Free Publications

Search for cll returned 203 results

Glossary Results

Relapsed CLL

CLL that responded to treatment but then returns.

Refractory CLL

CLL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same (stable disease).

CD38

An antigen on CLL cells and other cells. The expression of CD38 may be a marker to assist in predicting CLL progression.

Richter transformation

In a small number of patients, there is a progression in their disease. In these patients, CLL takes on the characteristics of an aggressive lymphoma. This change is not a second cancer, but a transformation of the CLL cells.

Small lymphocytic lymphoma (SLL)

A disease with symptoms and treatment that are much like CLL. SLL starts in a lymphocyte in a lymph node. CLL starts in a lymphocyte in the marrow.

Immunoglobulin Heavy Chain Variable Region (IgHv) Gene Status

A marker that can distinguish between CLL subtypes (unmutated IgHv and mutated IgHv). People with CLL with unmutated IgHv gene status may have a more progressive form of the disease.

Zap-70

An abbreviation for the cell protein “zeta-associated protein 70.” A high level of ZAP-70 expression on the cells of patients with B-cell CLL is one of several factors that may predict more progressive disease. Outside of a research laboratory this test is generally not very reliable and should not be used.

CLL Staging

Doctors use staging to help them predict chronic lymphocytic leukemia's (CLL's) progression and develop an appropriate treatment plan. Doctors use one of two staging systems: the Rai staging system or the Binet staging system. Both systems use physical examination and laboratory parameters to assess the extent of disease and to classify patients into three major prognostic groups.  Staging systems for CLL take into account: Abnormal increase in number of lymphocytes (lymp ...

  • Photo
Read more

Treating Chronic Lymphocytic Leukemia (CLL): Evaluating and Managing Options

June 11, 2015

Topics Covered How chronic lymphocytic leukemia (CLL) is diagnosed How chromosome changes help to plan treatment Standard and emerging therapies for CLL Side effects management The importance of open communication with your treatment team Speaker Rajat Bannerji, MD, PhD
Associate Professor of Medicine
Division of Hematology Oncology
Robert Wood Johnson Medical School
Rutgers, The State University of New Jersey
New ...

  • Photo
  • PDF
  • AUDIO
Read more

Medical Update for CLL, Maine

This program for healthcare professionals will provide a Medical Update on CLL including diagnostic testing, current therapies, including novel targeted therapies, and clinical trials.

Read more

NHL & CLL Diagnosis and Treatment Update

September 13, 2012

Topics Covered   Signs and symptoms of indolent and aggressive NHL subtypes & CLL Diagnosis and treatment planning for indolent and aggressive NHL subtypes & CLL Current and emerging treatment options for patients with indolent or aggressive NHL subtypes or CLL The importance of clinical trials in improving patient outcomes Side effects management and other survivorship issues for patients The importance of patient-provider communi ...

  • Photo
  • PDF
  • AUDIO
Read more

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) SUPPORT GROUP

The group will address specific issues related to a blood cancer diagnosis and will provide an opportunity for attendees to discuss concerns, anxieties, feelings related to illness, treatment and other related issues. The meetings are designed to provide mutual support and education to members by meeting with others whose situations are similar to their own. They are a resource to support coping, in conjunction with your or a loved one's medical treatment.

Read more

Pages

Glossary Results

Relapsed CLL

CLL that responded to treatment but then returns.

Refractory CLL

CLL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same (stable disease).

CD38

An antigen on CLL cells and other cells. The expression of CD38 may be a marker to assist in predicting CLL progression.

Richter transformation

In a small number of patients, there is a progression in their disease. In these patients, CLL takes on the characteristics of an aggressive lymphoma. This change is not a second cancer, but a transformation of the CLL cells.

Small lymphocytic lymphoma (SLL)

A disease with symptoms and treatment that are much like CLL. SLL starts in a lymphocyte in a lymph node. CLL starts in a lymphocyte in the marrow.

Immunoglobulin Heavy Chain Variable Region (IgHv) Gene Status

A marker that can distinguish between CLL subtypes (unmutated IgHv and mutated IgHv). People with CLL with unmutated IgHv gene status may have a more progressive form of the disease.

Zap-70

An abbreviation for the cell protein “zeta-associated protein 70.” A high level of ZAP-70 expression on the cells of patients with B-cell CLL is one of several factors that may predict more progressive disease. Outside of a research laboratory this test is generally not very reliable and should not be used.